Souzan Sanati

Author PubWeight™ 0.76^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.	Clin Cancer Res	2017	1.03
2	Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.	Cancer Med	2015	0.76
3	A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.	Clin Cancer Res	2017	0.75